Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial
Circulation: Cardiovascular Quality and Outcomes · 2024-05 · 17 (5)
DOI: 10.1161/circoutcomes.123.010335 ↗Kurz gefasst
Pragmatische Studie in der Zeitschrift Circulation: Cardiovascular Quality and Outcomes, 2024-05. Verfasst von Nimish N Shah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (N.N.S., K.F.F., T.A., F.P.W., N.R.D.). Hauptthemen laut MEDLINE: Biomarkers, Cholesterol, LDL, Electronic Health Records, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Lipid-lowering therapy (LLT) is underutilized for very high-risk atherosclerotic cardiovascular disease. PROMPT-LIPID (PRagmatic Trial of Messaging to Providers about Treatment of HyperLIPIDemia) sought to determine whether electronic health record (EHR) alerts improve 90-day LLT intensification in patients with very high-risk atherosclerotic cardiovascular disease. METHODS: PROMPT-LIPID was a pragmatic trial in which cardiovascular and internal medicine clinicians within Yale New Haven Health (New Haven, CT) were cluster-randomized to receive an EHR alert with individualized LLT recommendations or no alert for outpatients with very high-risk atherosclerotic cardiovascular disease and LDL-C (low-density lipoprotein cholesterol), ≥70 mg/dL. The primary outcome was 90-day LLT intensification (change to high-intensity statin and addition of ezetimibe or PCSK9i [proprotein subtilisin/kexin type 9 inhibitors]). Secondary outcomes included LDL-C level, proportion of patients with LDL-C of 2-fold increase in LLT intensification. EHR alerts, coupled with strategies to reduce clinician dismissal, may help address persistent gaps in LDL-C management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04394715, https://www.clinicaltrials.gov/ct2/show/study/NCT04394715
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (N.N.S., K.F.F., T.A., F.P.W., N.R.D.).
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, AL (L.G.).
- Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT (Y.Y., S.K., M.M., M.S., R.J.R., T.A., F.P.W., N.R.D.).
ORCID-Profile: Nimish N Shah, Lama Ghazi, Yu Yamamoto, Sanchit Kumar, Ralph J Riello Iii, Kamil F Faridi, Tariq Ahmad, F Perry Wilson
Zitieren
APA
Shah, N. N., Ghazi, L., Yamamoto, Y., Kumar, S., Martin, M., Simonov, M., Riello Iii, R. J., Faridi, K. F., Ahmad, T., Wilson, F. P., & Desai, N. R. (2024). Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation: Cardiovascular Quality and Outcomes, 17(5). https://doi.org/10.1161/circoutcomes.123.010335
Vancouver
Shah NN, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, et al. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation: Cardiovascular Quality and Outcomes. 2024;17(5). doi:10.1161/circoutcomes.123.010335
BibTeX
@article{Shah2024,
author = {Shah, Nimish N and Ghazi, Lama and Yamamoto, Yu and Kumar, Sanchit and Martin, Melissa and Simonov, Michael and Riello Iii, Ralph J and Faridi, Kamil F and Ahmad, Tariq and Wilson, F Perry and Desai, Nihar R},
title = {Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial},
journal = {Circulation: Cardiovascular Quality and Outcomes},
year = {2024},
volume = {17},
number = {5},
doi = {10.1161/circoutcomes.123.010335}
}
EUVIMED